Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amphotericin B for HIV-related talaromycosis (observational cohort)
ChiCTR2400082350Phase 4Not yet recruiting
- Sponsor
- Nanning Fourth People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of amphotericin b in talaromycosis and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Nanning Fourth People's Hospital. Primary endpoint: Clinical response rate at day 14. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
amphotericin b
03
Conditions
talaromycosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400082350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082350.